Eyepoint Pharmaceuticals Inc (EYPT)

Jan 16, 2025, 7:00 AM EST - 2 days ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 8, 2025, 7:00 AM EST - 10 days ago

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.

Dec 4, 2024, 7:00 AM EST - 6 weeks ago

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

Nov 14, 2024, 5:04 AM EST - 2 months ago

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

Nov 4, 2024, 7:00 AM EST - 2 months ago

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Oct 31, 2024, 4:00 PM EDT - 2 months ago

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

Oct 29, 2024, 9:47 PM EDT - 2 months ago

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

Oct 28, 2024, 5:14 PM EDT - 2 months ago

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

Oct 28, 2024, 7:00 AM EDT - 2 months ago

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

Oct 24, 2024, 7:00 AM EDT - 3 months ago

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

Sep 4, 2024, 7:00 AM EDT - 4 months ago

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

Aug 29, 2024, 5:35 PM EDT - 5 months ago

EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

Aug 8, 2024, 7:00 AM EDT - 5 months ago

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Jun 18, 2024, 7:00 AM EDT - 7 months ago

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

Jun 5, 2024, 7:00 AM EDT - 8 months ago

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 7:00 AM EDT - 9 months ago

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

May 7, 2024, 12:50 PM EDT - 9 months ago

EyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead Program

May 6, 2024, 9:10 AM EDT - 9 months ago

EyePoint Pharmaceuticals' stock plunges as eye treatment fails to meet trial goal

May 6, 2024, 7:00 AM EDT - 9 months ago

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy

Apr 2, 2024, 7:00 AM EDT - 10 months ago

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

Mar 7, 2024, 12:29 PM EST - 11 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call Transcript

Mar 7, 2024, 7:00 AM EST - 11 months ago

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

Mar 4, 2024, 7:00 AM EST - 11 months ago

EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer

Feb 29, 2024, 7:00 AM EST - 11 months ago

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024

Feb 21, 2024, 8:36 AM EST - 11 months ago

EyePoint Is Betting The Bank On EYP-1901

Feb 3, 2024, 4:20 PM EST - 1 year ago

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Jan 31, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 10, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema

Dec 20, 2023, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 5, 2023, 7:55 AM EST - 1 year ago

EyePoint (EYPT) stock price went parabolic: brace for a pullback

Dec 4, 2023, 5:06 PM EST - 1 year ago

EyePoint announces $175 million stock offering following record surge in share price

Dec 4, 2023, 7:40 AM EST - 1 year ago

EyePoint Pharmaceuticals' stock soars 362% after company announces positive data from trial of wet AMD treatment

AMD

Dec 4, 2023, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints

Nov 1, 2023, 1:03 PM EDT - 1 year ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2023 Earnings Conference Call Transcript

Nov 1, 2023, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments

Oct 31, 2023, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023

Oct 30, 2023, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Presentations at Eyecelerator 2023, American Academy of Ophthalmology Annual Meeting 2023 and Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference 2023

Oct 25, 2023, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 1, 2023

Oct 16, 2023, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team

Sep 11, 2023, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023

Aug 21, 2023, 8:31 AM EDT - 1 year ago

EyePoint: Well-Funded And Catalyst-Rich, But Not Without Risks

Aug 9, 2023, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

Aug 2, 2023, 1:10 PM EDT - 1 year ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2023 Earnings Call Transcript

Aug 2, 2023, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Developments

Jul 27, 2023, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Presents Interim Masked Safety Data and Patient Baseline Characteristics for DAVIO 2 Clinical Trial at OIS Retina Innovation Summit

Jul 26, 2023, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 2, 2023

Jul 10, 2023, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Chief Executive Officer Transition

Jun 5, 2023, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathy

May 31, 2023, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 30, 2023, 8:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals: A Puncher's Chance For Long Acting Eye Disease Drug Success